A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
Condition: HER2-negative Breast Cancer Interventions: Drug: AZD9833; Drug: Fulvestrant Sponsor: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Research | Study | Women